Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.64 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | ULK1 | O75385 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | DDX3X | O00571 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126328 | 0.93 | PTGS1 (0.68) | KCNK3KCNK9KCNH2PTGS1MEN1 | |
| SCHEMBL308208 | 0.90 | PTGS1 (0.72) | KCNK3KCNK9KCNH2PTGS1MEN1 | |
| SCHEMBL31171978 | 0.90 | PTGS1 (0.72) | KCNK3KCNK9KCNH2PTGS1MEN1 | |
| SCHEMBL1352405 | 0.88 | PTGS1 (0.68) | KCNK3KCNK9PTGS1MEN1KMT2A | |
| SCHEMBL20457020 | 0.88 | KCNK3 (0.82) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL17744817 | 0.87 | PTGS1 (0.64) | KCNK3KCNK9KCNH2PTGS1MEN1 | |
| SCHEMBL13381189 | 0.87 | MEN1 (0.67) | KCNK3KCNK9PTGS1MEN1KMT2A | |
| SCHEMBL8403932 | 0.86 | PTGS1 (0.72) | KCNK3KCNK9KCNH2PTGS1MEN1 | |
| SCHEMBL29568967 | 0.86 | PTGS1 (0.72) | KCNK3KCNK9KCNH2PTGS1MEN1 | |
| SCHEMBL11882113 | 0.86 | PTGS1 (0.59) | KCNK3KCNK9KCNH2PTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | KCNK3 616/4885KCNK9 782/4885KCNH2 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.